Homepage

Presentation

Tridek-One is a biotechnology company focused on developing first in class immunomodulatory products targeting the CD31 pathway. We are exploring a new approach for the management of immuno-inflammatory diseases. Our product has an holistic approach allowing a modulation of the immune response when overactivated.

Homepage

Presentation

Tridek-One is a biotechnology company focused on developing first in class immunomodulatory products targeting the CD31 pathway. We are exploring a new approach for the management of immuno-inflammatory diseases. Our product has an holistic approach allowing a modulation of the immune response when overactivated.

Investors-home

Investors

Two investment funds accompanying us in the development, Advent France Biotechnology and Advent Life Sciences which co-invested in the seed series.

Science-home

Science

The target of our product is a receptor named CD31 or PECAM1. Giuseppina Caligiuri and Antonino Nicoletti the lead researchers and co-founders of the company highlighted is role in the modulation of the immune response. CD31 is expressed on all the immune cells and on endothelial cells which confers to our product its holistic mechanism of action.